Press Releases

Emergent BioSolutions to Present at Cowen and Company 33rd Annual Health Care Conference

...

Read More

Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet

...

Read More

Emergent BioSolutions to Release Fourth Quarter and Full Year 2012 Financial Results and Conduct a Conference Call on March 7, 2013

...

Read More

Emergent BioSolutions Initiates Phase 2 Study in Pursuit of a Post-Exposure Prophylaxis Indication for BioThrax

...

Read More

Emergent BioSolutions Initiates Phase 2 Clinical Trial for Next Generation Anthrax Vaccine NuThrax

...

Read More

Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013

...

Read More

Emergent’s TRU-016 for CLL Receives Orphan Medicinal Product Designation from European Commission

...

Read More

Emergent BioSolutions Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate

...

Read More

Emergent BioSolutions to Present at 31st Annual J.P. Morgan Healthcare Conference

...

Read More

Emergent BioSolutions Appoints Robert G. Kramer as Chief Financial Officer

...

Read More

Emergent BioSolutions to Participate in Piper Jaffray’s 24th Annual Healthcare Conference

...

Read More

Emergent BioSolutions Announces Presentation on Bispecific Protein Therapeutic at 24th Annual EORTC-NCI-AACR Symposium

...

Read More